BioArctic and Eisai presented latest data regarding lecanemab at the AD/PDTM 2022 conference

BioArctic and its partner Eisai presented data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer’s disease (AD) – at the 16th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD. New data on blood biomarkers of amyloid and p-tau from the Phase 2b study in early Alzheimer’s disease was presented, as well as preliminary results from its ongoing open-label extension study. All data continue to support the effect of lecanemab with a continued low incidence of the side effect ARIA-E. The presentations also included an update on the development of a subcutaneous formulation, and data describing the unique binding profile of the drug candidate.